Supplementary Figure 3: Dinaciclib reduces the mRNA transcripts of Rad51, its paralogs and Brca1 in vivo from A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
Year: 2023
Type: supplementary-materials
Abstract: When tumor volumes had reached the predetermined limit, as indicated in Materials and Methods, the treatments were repeated for 24 h and tumors excised and immediately preserved in RNAlater. Total RNA was extracted from the tumors and subjected to RT-qPCR as described in the Materials and Methods. Results represent the mean {plus minus} SEM of at least 3 mice from each treatment group. *, **, *** and **** indicate significance of differences from DMSO controls, at p<0.05, 0.01, 0.001 and 0.0001, respectively.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362527059